Navigation Links
Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
Date:12/14/2010

or the treatment of other cancers, building on the broad potential of GITR as a fundamental mechanism involved in cancer as well as preclinical proof of concept studies of TRX518 in multiple models of established and metastatic cancer.

"Starting this first-in-human study with TRX518 in an oncology indication is an important milestone for Tolerx. TRX518 has a novel mechanism of action and has the potential to enhance an anti-tumor immune response, regardless of tumor type, and this has tremendous potential for a broad variety of malignancies," said Louis Vaickus, MD, Chief Medical Officer at Tolerx.  "TRX518 works through GITR (glucocorticoid-induced tumor necrosis factor receptor), a molecule that has been recognized by the National Cancer Institute and other experts as one of the most promising targets in cancer immunotherapy."

About TRX518

TRX518 is a targeted T cell immunotherapy that activates GITR (glucocorticoid-induced tumor necrosis factor receptor) found on multiple types of T cells and other immune cells. Activated GITR plays a role in directing the anti-tumor immune response via activating tumor-antigen-specific T effector cells, as well as abrogating the suppression induced by inappropriately activated T regulatory cells.  In preclinical studies, TRX518 achieved its targeted effect without compromising normal immune function, and preclinical models suggest TRX518 may have a reduced risk of causing serious inflammatory side effects that can result from cytokine release.  TRX518 is designed to have activating and sustaining effects on T cells for enhancing the immune system's responses against cancer cells, including responses that may occur with TRX518 alone, as well as complementary responses in combination with other cancer therapies including vaccines.  

About Tolerx

Tolerx, Inc., a world leader in the understanding of T cell function, is developing novel therapies intended to treat
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress
2. Tolerx Announces Amendment to Phase 3 DEFEND Protocol
3. Tolerx Expands Phase 3 DEFEND Trial of Otelixizumab in Europe
4. Laureate Announces Manufacturing Agreement with Tolerx
5. Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety
6. GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
7. SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK
8. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
9. Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
10. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
11. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... EPFL and the University of  Geneva ... John P. Donoghue . The American neuroscientist is ... . The new Wyss Center for Bio- ... Geneva , has named as its director one ... Donoghue , founder of Brown University,s Institute for Brain ...
(Date:7/10/2014)... 2014 Women in the West ... an additional family planning option. Sayana® Press has ... all levels of the health system and in ... widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with the ... the first of four African countries expected to ...
(Date:7/10/2014)... Terascala, the industry leader in HPC ... former vice president of product management for Flexera Software, ... marketing. Terascala’s software when combined with leading compute and ... performance and most reliable solutions for processing big data. ... expansion and broaden its product portfolio. His leadership in ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been ... comes with a second treatment cup to help prevent and ... cup is thinner on the edges for a softer contact ... and uneven surfaces on the face, neck and décolleté. Choose ... on areas such as the cheeks and neck, or opt ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... Kingdom and GAITHERSBURG, Md., Oct. 29 /PRNewswire/,-- ... name to MedImmune to,reflect AstraZeneca,s vision for ... will unite the resources and expertise from ... activities within the AstraZeneca,Group, under the "MedImmune" ...
... the Innovator in,Ultrasound for more than 50 years, announced ... for advanced cardiac and,vascular imaging, the ProSound Alpha 10 ... American Heart Association, at the Orange County,Convention Center in ... 7 and the Alpha 10 incorporate all of the ...
... WaferGen Biosystems,Inc. (OTC Bulletin Board: WGBS), a ... and stem cell research systems,today announced that Mr. ... a corporate presentation at the Acumen BioFin Rodman,& ... be held,November 5 - 7, 2007, at the ...
Cached Biology Technology:AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune 2ALOKA to Introduce New 'ProSound' Diagnostic Ultrasound Systems at the Scientific Session 2007 of American Heart Association, 4th to 7th of November 2007 in Orlando, Florida 2ALOKA to Introduce New 'ProSound' Diagnostic Ultrasound Systems at the Scientific Session 2007 of American Heart Association, 4th to 7th of November 2007 in Orlando, Florida 3WaferGen to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2
(Date:7/11/2014)... is creating a new professorship in tissue engineering ... for Molecular Engineering and the Marine Biological Laboratory, ... Millicent and Eugene Bell Foundation., The Eugene Bell ... Institute for Molecular Engineering. That endowed chair holder ... MBL,s Eugene Bell Center for Regenerative Biology and ...
(Date:7/11/2014)... the National Institute of Standards and Technology (NIST) ... more effectively, they often prove that necessity is ... case recently for M. Lorna De Leoz and ... specialization of glycomics. Glycomics is the study of ... are attached to proteins and lipids and influence ...
(Date:7/11/2014)... relationships with other group members to reduce aggression and ... the strategy for grooming activities shows a certain pattern ... the scientific journal Biology Letters . , Grooming ... practiced without ulterior motives. To be groomed has hygienic ... grooming another individual can provide access to infants, mating ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2Baboons groom early in the day to get benefits later 2
... N.J. March 28, 2013 - Deborah E. Wiley, Chair of ... & JWb) will present the 2013 Wiley Prize in Biomedical ... Brandeis University (Emeritus), and Dr. Michael Rosbash, Brandeis University on ... Caspary Auditorium, The Rockefeller University, 1230 York Avenue, New York, ...
... can add up to a lot. In short, that,s ... streams and pollution by Steve Powers, a postdoctoral researcher ... (ECI). "Small dams, reservoirs and ponds trap water ... Powers said. "This is especially relevant in agricultural lands ...
... , March 28, 2013  Lockheed Martin [NYSE: ... aimed at expanding its collaboration with Silicon Valley ... the federal government. Called the ... will provide the federal government with greater visibility ...
Cached Biology News:2013 Wiley Prize to be awarded at Apr. 5 event 2Notre Dame researcher is studying role small dams play in pollution control 2Lockheed Martin Launches Technology Hub To Connect Silicon Valley Innovators With Federal Government Needs 2
... Digital Sight DS-L2 imaging controller is a ... DS-L1, and allows users to comfortably observe, ... DS-L2 controller features an 8.4 inch LCD ... variety of Nikon cameras including the DS-Fi1 ...
... a premium quality recombinant form of Thermus ... suitable for a wide range of PCR ... reproducible performance, each preparation is extensively tested ... NovaTaq DNA Polymerase possesses an integral 5′→3′ ...
Mouse polyclonal antibody raised against a partial recombinant TSEN2. NCBI Entrez Gene ID = 80746...
Mouse polyclonal antibody raised against a partial recombinant NCLN. NCBI Entrez Gene ID = 56926...
Biology Products: